chlamydia vaccineclinical trialSTI prevention
An early-stage clinical trial for a chlamydia vaccine reported in The Lancet Infectious Diseases shows promising results, marking a significant step toward combating the most common bacterial STI in the U.S.

The phase 1 trial, conducted by UK and Danish researchers, found the vaccine safe and capable of inducing an immune response. This development is crucial as there is no existing vaccine against chlamydia, which is a leading cause of infertility and can result in significant health issues like pelvic inflammatory disease. The trial, involving healthy individuals who received various dosages over four months, sets the stage for a larger phase 2 study focusing on the vaccine's effectiveness.